Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From DexCom, Inc.
Dexcom may be planning to purchase Insulet to enter the insulin pump market and transform itself into a diabetes tech giant.
Bayer is handing back rights to two early-stage off-the-shelf CAR-Ts to Atara, but the split could still be good news for the biotech company.
The big pharma company and its new partner both expect demand to continue for pre-exposure prophylaxis antibody therapies, for COVID-19 and beyond.
While it is still early days for Caribou, early signs suggest it could have the first off-the-shelf program to rival established CAR-T therapies.
- Monitoring Equipment & Devices
In Vitro Diagnostics
- Glucose Testing
- Other Names / Subsidiaries
- SweetSpot Diabetes Care
- TypeZero Technologies, LLC